Retatrutide (LY3437943) is a next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — sometimes described as “GLP-3” activity. Its ~6-day plasma half-life supports weekly dosing. Phase 2 NEJM data showed up to −28.7% mean body weight reduction at 48 weeks — the highest ever recorded in a clinical peptide trial.
- Triple receptor agonism — GLP-1 + GIP + glucagon receptor activation via three independent signalling cascades.
- Highest recorded weight loss — up to −28.7% mean body weight in Phase 2 trial (NEJM published).
- Increased energy expenditure — glucagon receptor component stimulates thermogenesis and fatty acid oxidation.
- Hepatic lipid metabolism — significant reductions in liver fat, ALT, AST, cholesterol, and triglycerides.
⚠️ For research use only. Not for human or animal consumption. Store at −20°C. Reconstitute with Bacteriostatic Water.
Reviews
There are no reviews yet.